Lichtenberg Michael K W, de Graaf Rick, Stahlhoff Wilhelm F, Özkapi Ahmet, Rassaf Tienush, Breuckmann Frank
1 Department of Angiology, Arnsberg Medical Center, Arnsberg, Germany.
2 Department of Cardiology, Arnsberg Medical Center, Arnsberg, Germany.
Vasa. 2019 Mar;48(2):175-180. doi: 10.1024/0301-1526/a000763. Epub 2018 Nov 19.
We sought to determine the patency and clinical symptom relief of the Venovo venous stent in the endovascular treatment of non-thrombotic (NIVL) or post-thrombotic venous obstruction (PTO) of the iliofemoral track over a period of 6 months.
A total of 80 patients (45 female, mean age 57 years) treated in 2016 and 2017 were included in the Arnsberg venous registry. Clinical improvement was determined by the revised venous clinical severity score (rVCSS) as well as the clinical, etiologic, anatomic and pathophysiologic (CEAP) score. Primary and secondary stent patency was evaluated using duplex ultrasound.
Overall 6-months patency rates were 98 % for primary and 100 % for secondary patency. For NIVL primary patency was 97 %, whereas for PTO primary patency was 96 %. Early stent re-occlusion occurred in 3 patients within 34, 59 and 156 days after intervention. Two of these patients were successfully treated by endovascular mechanical thrombectomy and stent in stent implantation. Clinical improvement with a gain of ≥ 2 rVCSS levels was observed in 51 %. CEAP scores decreased from 4.3 to 2.7.
In this first time report the novel Venovo venous stent showed adequate patency rates associated with reasonable clinical improvement and low device-related complications throughout a 6-months-follow-up in both NIVL and PTO.
我们试图确定Venovo静脉支架在髂股静脉非血栓形成(NIVL)或血栓形成后静脉阻塞(PTO)的血管内治疗中6个月内的通畅率和临床症状缓解情况。
2016年和2017年治疗的80例患者(45例女性,平均年龄57岁)纳入阿恩斯贝格静脉登记处。通过修订的静脉临床严重程度评分(rVCSS)以及临床、病因、解剖和病理生理(CEAP)评分来确定临床改善情况。使用双功超声评估支架的原发和继发通畅情况。
总体6个月的原发通畅率为98%,继发通畅率为100%。NIVL的原发通畅率为97%,而PTO的原发通畅率为96%。3例患者在干预后34、59和156天内发生早期支架再闭塞。其中2例患者通过血管内机械血栓切除术和支架内植入支架成功治疗。51%的患者临床改善,rVCSS水平提高≥2级。CEAP评分从4.3降至2.7。
在这份首次报告中,新型Venovo静脉支架在NIVL和PTO的6个月随访中显示出足够的通畅率,伴有合理的临床改善和较低的器械相关并发症。